Parminder Bhatia Brings Healthcare AI Expertise to Helio Genomics Board
Parminder Bhatia, a veteran leader in the healthcare AI space, has joined the board of directors at Helio Genomics, a company pioneering AI-powered precision liver diagnostics.
The appointment was announced on July 16, 2026, by Helio Genomics, a commercial-stage company that’s developed an AI-driven platform to detect liver cancer and other diseases in their early stages. This approach enables at-risk patients to receive timely treatment and improve their chances of survival.
Bhatia, who most recently served as Chief Innovation Officer at Optum – a leading healthcare services company – brings over two decades of experience in healthcare and technology. His expertise spans AI strategy, data analytics, and digital transformation, making him an ideal fit for Helio Genomics.
As a member of the board, Bhatia will help guide Helio Genomics in its mission to transform liver disease management through AI. His appointment is seen as a significant boost to the company’s growth prospects, particularly given the growing demand for precision medicine and AI-driven diagnostics.
Helio Genomics has already made significant strides in the liver disease space, with its AI platform showing impressive results in early cancer detection and disease surveillance. The company’s technology has the potential to revolutionize the way liver diseases are diagnosed and treated, and Bhatia’s expertise will be instrumental in driving this transformation forward.
A New Era in Liver Disease Management
The addition of Bhatia to the Helio Genomics board signals a new era in liver disease management. With AI playing an increasingly important role in healthcare, companies like Helio Genomics are poised to revolutionize the way diseases are diagnosed and treated.
What This Means
For patients with liver disease, this development means better access to early detection and treatment. By leveraging AI-powered diagnostics, healthcare providers can identify liver cancer and other diseases at an earlier stage, leading to improved patient outcomes and increased survival rates.
